Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_assertion type Assertion NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_head.
- NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_assertion description "[Patient proportions with TP53 defects at diagnosis or before first therapy were reported within the range 5-15 %, but they increase dramatically in pretreated cohorts (reported up to 44 %), and also in patients with Richter transformation (50 % harbor TP53 defects).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_provenance.
- NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_assertion evidence source_evidence_literature NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_provenance.
- NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_assertion SIO_000772 24014294 NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_provenance.
- NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_assertion wasDerivedFrom befree-20140225 NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_provenance.
- NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_assertion wasGeneratedBy ECO_0000203 NP803410.RAShbXE9B_qJ-Gj0BmaB-lvEq9zOWun_NTw82XP5VwXjI130_provenance.